Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Cancer 5, 573–580 (1 July 2005) | doi:10.1038/nrc1651
Killing time for cancer cells
&
Abstract
As the signalling pathways that control cellular proliferation and death are unravelled, a range of targets have emerged as candidates for molecular cancer therapy. For their survival, cancer cells depend on a few highly activated signalling pathways; inhibition of these pathways has a strong apoptotic effect and can lead to tumour regression. But drugs that exploit this weakness, such as imatinib, have not cured patients: withdrawal of the drug leads to disease recurrence, and sustained treatment leads to the emergence of drug-resistant clones. Can cancer be cured, or will it have to be controlled as a chronic disease?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
